

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**丽珠医药**  
**LIVZON**

**麗珠醫藥集團股份有限公司**

**LIVZON PHARMACEUTICAL GROUP INC.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1513)**

## **RELEASING OF PLEDGED SHARES HELD BY A CONTROLLING SHAREHOLDER**

Reference is made to the announcements of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 29 May 2014 and 19 September 2016 in respect of the pledge of shares and releasing a portion of pledged shares held by a controlling shareholder respectively.

The Company noted on 29 May 2014, by a notice from Topsino Industries Limited (天誠實業有限公司) (“**Topsino**”), a wholly-owned subsidiary of Joicare Pharmaceutical Industry Group Co., Ltd. (健康元藥業集團股份有限公司) (“**Joicare**”) which is the Company’s controlling shareholder, that Topsino has entered into an equity interests pledge agreement with Nanyang Commercial Bank to pledge its 16,000,000 H Shares of the Company (the number of shares was increased to 20,800,000 shares after the Company’s implementation of 2014 Equity Distribution) to Nanyang Commercial Bank.

On 15 August 2017, the Company received a notice from Topsino that Topsino released the pledge of its 16,250,000 H shares of the Company from Nanyang Commercial Bank. The relevant formalities for the release of pledge have been completed. The released pledged shares represent approximately 2.94% of the total number of the shares of the Company (553,231,369 shares). As at the date of this announcement, no shares of the Company held by Topsino are pledged.

As at the date of this announcement, Joincare, the Company's controlling shareholder, directly and indirectly, holds and controls a total of 247,857,176 shares of the Company, representing approximately 44.80% of the total number of the shares of the Company. Among which, Topsino directly holds 96,665,487 H shares of the Company, representing approximately 17.47% of the total number of the shares of the Company.

Investors and shareholders are advised by the board of directors of the Company to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Livzon Pharmaceutical Group Inc. \***  
麗珠醫藥集團股份有限公司  
**Yang Liang**  
*Company Secretary*

Zhuhai, China

15 August 2017

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Xu Guoxiang (Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Qiu Qingfeng and Mr. Zhong Shan; and the Independent Non-Executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.*

*\* For identification purpose only*